
BioHarvest Sciences Inc. (NASDAQ:BHST – Free Report) – Research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of BioHarvest Sciences in a report issued on Monday, November 16th. HC Wainwright analyst A. Dayal now forecasts that the company will earn ($0.62) per share for the year, down from their prior forecast of ($0.59). The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q4 2026 earnings at ($0.19) EPS, FY2027 earnings at ($0.25) EPS, FY2028 earnings at $0.11 EPS, FY2029 earnings at $0.56 EPS and FY2030 earnings at $1.12 EPS.
Other equities research analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Monday, September 14th. Maxim Group decreased their price target on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. Finally, Roth Capital decreased their price target on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $6.50.
BioHarvest Sciences Stock Performance
Shares of NASDAQ:BHST opened at $1.32 on Wednesday. BioHarvest Sciences has a 52 week low of $0.91 and a 52 week high of $7.20. The company has a market capitalization of $25.90 million, a PE ratio of -2.49 and a beta of 0.93. The company has a 50 day moving average price of $1.60 and a two-hundred day moving average price of $3.00.
BioHarvest Sciences (NASDAQ:BHST – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. The business had revenue of $7.87 million for the quarter, compared to analyst estimates of $9.31 million. BioHarvest Sciences had a negative net margin of 34.67% and a negative return on equity of 55.88%.
Hedge Funds Weigh In On BioHarvest Sciences
An institutional investor recently raised its position in BioHarvest Sciences stock. TD Waterhouse Canada Inc. lifted its holdings in BioHarvest Sciences Inc. (NASDAQ:BHST – Free Report) by 83.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 43,827 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. TD Waterhouse Canada Inc. owned about 0.22% of BioHarvest Sciences worth $64,000 as of its most recent SEC filing.
About BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company that develops plant-based ingredients and consumer products using its proprietary Botanical Synthesis platform. The technology grows selected plant cells in controlled bioreactors, offering an alternative to cultivating and processing whole plants. The company’s best-known product is VINIA, a dietary supplement made from red grape cells. BioHarvest also works to develop additional botanical ingredients and products for consumer markets, including nutraceuticals and cosmetics.
Read More
- Five stocks we like better than BioHarvest Sciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
